StockNews.AI
PFE
StockNews.AI
160 days

ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP

1. ViiV Healthcare reports zero cases of HIV acquisition with Apretude. 2. Cabenuva shows effective results in real-world data over three years.

2m saved
Insight
Article

FAQ

Why Bullish?

The positive data on Apretude and Cabenuva enhances Pfizer’s reputation in HIV treatment. Similar past announcements have led to an uptick in share prices for pharmaceutical firms.

How important is it?

The article provides significant insight into Pfizer's ongoing investment in HIV treatments, which can affect market perception and stock performance.

Why Long Term?

Long-term adoption of Apretude and Cabenuva can boost Pfizer's market presence and future revenues, as sustained positive outcomes can solidify pharmaceutical leadership.

Related Companies

GSKSHIONOGI
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV acquisition for Apretude, the only long-acting injectable approved for HIV prevention. Real-world data were also presented for Cabenuva, the only approved, complete long-acting injectable treatment regimen, showing its effectiveness in the three years since it has been avail.

Related News